Vol. 7, Issue 1, Part B (2025)

In 2025, peptic ulcers-which are mostly brought on by Helicobacter pylori infections and long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs)-remain a major global health concern. Significant progress has been made in the last ten years in our understanding of the pathogenesis, diagnosis, and management of peptic ulcers. This article examines the most recent findings about the function of H. pylori, the influence of the gut microbiota, and the growing worries about antibiotic resistance. Additionally, it assesses how proton pump inhibitors (PPIs), a mainstay of ulcer treatment, are changing as more recent substitutes, such as potassium-competitive acid blockers (P-CABs), gain popularity. Furthermore, the manner ulcers are identified and treated is changing due to developments in non-invasive diagnostics and endoscopic technology. Additionally, the paper explores personalized medicine, explaining how biomarker-based approaches and genomic profiling are opening the door to more individualized and successful treatment regimens. The article also discusses lifestyle factors, including smoking, stress, and food, and their increasing significance in management and prevention. It concludes by examining the possibility of H. pylori vaccinations and ulcer treatment in the future, emphasizing the fascinating idea of precision medicine that has the potential to significantly enhance patient outcomes. In summary, the treatment of peptic ulcers is changing dramatically, using tailored techniques, contemporary pharmacology, and diagnostics to enhance patient outcomes and care in 2025 and beyond.